Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives

Table 2 Outcomes after transarterial radioembolization from recent studies (modified from Kim et al[89])

Ref.	No. of patients	Response rate	Survival (mo)	Prognostic factors
Carr et al[48]	65	OR = 38%	Okuda et al[90] I: 21 Okuda et al[90] II: 10
Salem et al[50]	43	PR = 47%	Okuda et al[90] I: 24 Okuda et al[90] II: 13	Main PVTT; AFP > 400 ng/mL tumor burden > 25%
Sangro et al[91]	24	PR = 24%; SD: 64%	7
Young et al[80]	41		Okuda et al[90] I: 21.7 Okuda et al[90] II: 14.2
Kulik et al[92]	71	PR = 42%; SD: 35%	15.5
Salem et al[63]	123	RR = 72%	20.5	Sex (female); Child-Pugh class; UNOS
Sangro et al[8]	325		12.8	ECOG; nodules > 5; INR > 1.2; extrahepatic disease
Mazzaferro et al[56]	52	CR = 9.6%; OR = 40.4%	15	Response; Child Pugh class

PVTT: Portal vein tumour thrombosis; AFP: Alpha-fetoprotein; OR: Odds ratio; PR: Partial response; RR: Response rate; CR: Complete response; SD: Stable disease; UNOS: United Network of Organ Sharing; ECOG: European Cooperative Oncology Group; INR: International Normalized Ratio.